Page 6 - Activating Construct News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Activating construct. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Activating Construct Today - Breaking & Trending Today

Harpoon Therapeutics (HARP) Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort

Harpoon Therapeutics (HARP) Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New York , United States , Luke Walker , European Society For Medical Oncology , Roche Ltd , Harpoon Therapeutics Inc , Harpoon Therapeutics , Master Clinical Supply Agreement , Chief Medical Officer , Atezolizumab Combination Cohort , European Society , Medical Oncology , Investor Relations , Activating Construct ,

AbbVie ditches license option for Harpoon's TriTAC multiple myeloma program

Going forward, Harpoon said the TriTAC multiple myeloma program will remain exclusively within the company as it plans to complete an ongoing Phase 1 clinical trial with data to support the next phase of development. ....

Julie Eastland , Haibo Wang , Harpoon Therapeutics , Activating Construct , Hummingbird Bioscience ,

Harpoon Therapeutics (HARP) Provides an Update on the HPN217 Development and Deal with AbbVie (ABBV)

Harpoon Therapeutics (HARP) Provides an Update on the HPN217 Development and Deal with AbbVie (ABBV)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Roberth Uhl , Julie Eastland , International Myeloma Society , Exchange Commission , European Society For Medical Oncology , Harpoon Therapeutics Inc , Harpoon Therapeutics , Option Agreement , Annual Meeting , European Society , Medical Oncology , Activating Construct , Private Securities Litigation Reform Act , Harpoon Therapeutic ,

Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of the parties’ Development and Option Agreement in connection with Harpoon’s HPN217 program, which targets B cell maturation antigen, or BCMA. The Agreement, which will terminate effective October 12, 2023, g ....

Julie Eastland , Roberth Uhl , Exchange Commission , European Society For Medical Oncology , Harpoon Therapeutics Inc , International Myeloma Society , Option Agreement , Annual Meeting , European Society , Medical Oncology , Activating Construct , Harpoon Therapeutics , Private Securities Litigation Reform Act , Harpoon Therapeutic ,

Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie - Harpoon Therapeutics (NASDAQ:HARP)

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has ....

Julie Eastland , Roberth Uhl , Harpoon Therapeutics Inc , Exchange Commission , European Society For Medical Oncology , International Myeloma Society , Option Agreement , Annual Meeting , European Society , Medical Oncology , Activating Construct , Harpoon Therapeutics , Private Securities Litigation Reform Act , Harpoon Therapeutic ,